HIV and AIDS Trial, Recruiting NCT07643948 Sponsor: Chinese University of Hong Kong Condition: HIV and AIDS
Back to Hiv Aids

HIV and AIDS Trial, Recruiting

NCT07643948
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older who are living with HIV and currently taking antiretroviral therapy (HIV medications)
  • People whose HIV viral load (the amount of virus in the blood) has been below 20 copies/mL at two separate tests over at least 6 months, and whose doctor is planning to switch them to a different medication regimen
  • People who meet the age requirement but are not planned for a medication switch may be eligible for the control group, including those with low-level viremia — meaning two or more consecutive blood tests showing a viral load between 21 and 200 copies/mL in the past two years (confirm with trial site)

Who may not be able to join:

  • People who are currently pregnant
  • People whose HIV treatment is not working (known as virologic failure), meaning the virus is not being adequately controlled by their current medications
  • People who are currently experiencing an opportunistic infection (a serious infection that occurs when the immune system is weakened)
  • People who are currently incarcerated (in prison)
  • People who are not able to give their own informed consent to participate
  • People who have a mental illness (confirm with trial site regarding specific conditions affected)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Shui Shan Lee, MD, S.H. Ho Research Centre for Infectious Diseases, The Chinese University of Hong kong

Phone: +852 22528812

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 October 2025
Est. completion
30 September 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Proportional difference of drug resistance mutation at short term after regimen switch; Proportional difference of drug resistance mutation at long term after regimen switch

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov